| ￥3500 | |
| Z04181-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized CD27/TNFRSF7, His, Human at 0.5μg/ml (100μl/well) on the plate can bind Human CD27 Ligand, hFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 18.1 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
Immobilized CD27/TNFRSF7, His, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Human CD27 Ligand, hFc Tag with the EC50 of 12.6 ng/ml determined by ELISA. »
The purity of CD27/TNFRSF7, His, Human is greater than 95% as determined by SEC-HPLC. »
CD27/TNFRSF7, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | CD27, also known as TNFRSF7, is an approximately 55 kDa transmembrane protein in the TNF receptor superfamily. It functions as a co‑stimulatory molecule that supports lymphocyte activation and survival. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. |
| Synonyms | CD27 antigen; Tp55; TNFRSF7; S152; T14; S152. LPFS2; MGC20393; S152CD27L receptor |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
